Page last updated: 2024-12-10

ribose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth

Description

ribopyranose : The pyranose form of ribose. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID10975657
CHEBI ID47006
CHEBI ID47007
CHEBI ID33942
CHEBI ID16988
SCHEMBL ID339948
MeSH IDM0019077

Synonyms (31)

Synonym
d ribose
RIB ,
RIBOSE ,
d-ribose ,
(3r,4r,5r)-tetrahydro-2h-pyran-2,3,4,5-tetrol
d-ribopyranose ,
CHEBI:47006
10257-32-6
(3r,4r,5r)-tetrahydro-2h-pyran-2,3,4,5-tetraol
SCHEMBL339948
d-rib
ribopyranose
d-ribopyranoside
ribopyranoside
C21057
DTXSID70450356
ec 700-481-3
SRBFZHDQGSBBOR-SOOFDHNKSA-N
10257-33-7
ribopyranose (7ci,8ci,9ci)
(3r,4r,5r)-oxane-2,3,4,5-tetrol
Q27120754
ribiose
EN300-1704373
ribopyranose(7ci,8ci,9ci)
rel-(3r,4r,5r)-tetrahydro-2h-pyran-2,3,4,5-tetrol
chebi:47007
ribo-pentose
chebi:33942
chebi:16988
d-ribo-pentose

Research Excerpts

Toxicity

Ribose supplementation is safe and does not cause glycation in vivo. It has been suggested that ingestion of d-ribose might promote the formation of glycated proteins in vivo with potential adverse consequences.

ExcerptReferenceRelevance
"Antioxidant drugs have been reported to protect pancreatic islets from the adverse effects of chronic exposure to supraphysiological glucose concentrations."( A role for glutathione peroxidase in protecting pancreatic beta cells against oxidative stress in a model of glucose toxicity.
Harmon, J; Robertson, RP; Tanaka, Y; Tran, PO, 2002
)
0.31
"4 g/kg body weight/day in male and female rats, respectively, as being the absolute no observed adverse effect level (NOAEL) for this substance."( Sub-chronic (13-week) oral toxicity study with D-ribose in Wistar rats.
Borzelleca, JF; Griffiths, JC; St Cyr, J, 2007
)
0.34
" In summary, administration of DR to pregnant rats at concentrations up to 20% of the diet resulted in no significant adverse effects on the developing embryo/fetus at doses that were not otherwise a severe metabolic stress on the dam."( Lack of oral embryotoxicity/teratogenicity with D-ribose in Wistar rats.
Borzelleca, JF; Griffiths, JC; St Cyr, J, 2007
)
0.34
" Moreover, D-ribosylated Tau aggregates were highly toxic to SHSY5Y cells and resulted in both apoptosis and necrosis."( D-Ribosylated Tau forms globular aggregates with high cytotoxicity.
Chen, L; He, R; Wang, X; Wei, Y, 2009
)
0.35
" The development of an effective and clinically safe therapeutic regimen using the intravenous route in critically ill patients especially with cardiac diseases requires a comprehensive assessment of potential toxic effects of the drug in laboratory animals and in human beings."( Evaluation of α-D-ribofuranose (D-ribose) toxicity after intravenous administration to rabbits.
Abu-Baker, N; Abu-Tayeh, R; Al-Essa, MK; Al-Hadidi, K; Al-Omari, B; Al-Saleh, A; Al-Zhgoul, M; Alzoubi, K; Battah, A; Ismail, ZB; Khlouf, S; Shomaf, M, 2012
)
0.38
" However, as a reducing sugar, it has been suggested that ingestion of d-ribose might promote the formation of glycated proteins in vivo with potential adverse consequences."( (D)-Ribose supplementation in the equine: lack of effect on glycated plasma proteins suggesting safety in humans.
Caiazzo, C; Sinatra, ST, 2015
)
0.42
" No adverse effects were reported."( (D)-Ribose supplementation in the equine: lack of effect on glycated plasma proteins suggesting safety in humans.
Caiazzo, C; Sinatra, ST, 2015
)
0.42
"Ribose supplementation is safe and does not cause glycation in vivo."( (D)-Ribose supplementation in the equine: lack of effect on glycated plasma proteins suggesting safety in humans.
Caiazzo, C; Sinatra, ST, 2015
)
0.42
" Moreover, the chemically modified U-rich crRNA achieved very safe and highly specific genome editing in murine zygotes."( Highly efficient and safe genome editing by CRISPR-Cas12a using CRISPR RNA with a ribosyl-2'-O-methylated uridinylate-rich 3'-overhang in mouse zygotes.
Ha, DI; Kim, D; Kim, YS; Ko, JH; Lee, JM; Lee, NE, 2020
)
0.56
"No dose-limiting adverse effects were noted in any dog."( Safety and efficacy of a ribose-cysteine supplement to increase erythrocyte glutathione concentration in healthy dogs.
Hohenhaus, AE; Leibman, NF; Mosher, BA; Verrilli, AM, 2021
)
0.62
"The RibCys supplement was safe and well tolerated in all dogs."( Safety and efficacy of a ribose-cysteine supplement to increase erythrocyte glutathione concentration in healthy dogs.
Hohenhaus, AE; Leibman, NF; Mosher, BA; Verrilli, AM, 2021
)
0.62
" There were no statistical differences in other adverse events among these three groups."( Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Cao, L; Li, Y; Wang, J; Yu, X; Zhang, M, 2021
)
0.62
" With the incorporation of poly (ADP-ribose) polymerase inhibitors (PARPi) into maintenance treatment regimens, the management of short- and long-term adverse events are key clinical priorities."( PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
Burges, A; Chelariu-Raicu, A; Czogalla, B; Harbeck, N; Hester, A; Mahner, S; Trillsch, F; Wuerstlein, R, 2023
)
0.91
" Pharmacovigilance studies were conducted by collecting cases of PARPi-related interstitial lung disease from the FDA Adverse Events Reporting System and assessing disproportionalities by reporting ORs and information components."( Interstitial lung disease in patients treated with poly (ADP-ribose) polymerase inhibitors (PARPi): analysis of results from clinical trials and the FDA Adverse Events Reporting System database.
Gao, S; He, Z; Huang, M; Jiang, W; Lam, K; Li, Y; Mo, J; Qiu, K; Wu, J; Yang, S; Zhu, J, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" The procedure was applied to pharmacokinetics in the dog and a two-compartment body model was observed with a terminal half-life of 103-130 min."( Properties, stability, assay, and preliminary pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'(N',N'-dimethylamino-n-propyl)-D-glucofuranose hydrochloride.
Garrett, ER; Mahrous, H; Schuermann, W; Van Peer, A, 1982
)
0.26
" D-ribose was absorbed rapidly with mean Tmax ranging between 18 and 30 minutes."( Evaluation of D-ribose pharmacokinetics, dose proportionality, food effect, and pharmacodynamics after oral solution administration in healthy male and female subjects.
Homer, K; Khankari, R; Neutel, J; Shah, A; Tempero, K; Thompson, J, 2014
)
0.4
" In this review, we give an overview of the pharmacokinetic properties of the four PARP inhibitors, including considerations for patients with renal dysfunction or hepatic impairment, the effect of food, and drug-drug interactions."( Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Beijnen, JH; Bruin, MAC; Huitema, ADR; Sonke, GS, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" We therefore studied its functional and metabolic effects in closed chest rats when given in combination with prazosin, verapamil or metoprolol, all of which have direct effects on the circulation."( Functional and metabolic effects of ribose in combination with prazosin, verapamil and metoprolol in rats in vivo.
Lortet, S; Zimmer, HG, 1989
)
0.28
"The aim of this study is to establish whether a supplement of creatine and ribose combined with a physical exercise program can improve the total work capacity during exercise in a population of patients with known ischemic heart disease."( A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease.
Catena, G; D'Angelo, A; Derosa, G; Maffioli, P; Maggi, A; Pasqualotto, S, 2019
)
0.51
" She underwent concurrent radiotherapy and chemotherapy according to the Stupp protocol in combination with a multi-target antiangiogenic drug and additional intrathecal chemotherapy using methotrexate."( Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report.
Du, F; Jiang, W; Ren, Y; Sun, Y; Wang, Z, 2021
)
0.62
" Here, we investigated the tolerability, safety, and preliminary antitumor activity of camrelizumab, an anti-PD-1 antibody, in combination with apatinib, a vascular endothelial growth factor receptor-2 inhibitor, and fuzuloparib, a PARP inhibitor, in patients with recurrent or metastatic TNBC."( A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Li, H; Li, S; Ouyang, Q; Shao, B; Tong, Z; Wang, Y; Xu, G; Zhang, Q, 2022
)
0.72

Bioavailability

D-ribose is much more active in protein glycation as compared with D-glucose. The intestinal absorption rate of orally administered ribose was 87.

ExcerptReferenceRelevance
" The intestinal absorption rate of orally administered ribose was 87."( Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiency.
Gross, M; Reiter, S; Zöllner, N, 1989
)
0.28
"0 g) permitted an estimate of 63 +/- 4 (SEM)% bioavailability from urinary recovery of drug, with estimated terminal half-lives of 454 +/- 25 min from minimal data."( Pharmacokinetics of the immunomodulatory 1,2-O-isopropylidene-3-O-3'-(N',N'-dimethyl-amino-n-propyl)-D-glucofuranose hydrochloride in normal human volunteers.
Altmayer, P; Garrett, ER; Lücker, P; Schuermann, W; Van Peer, A, 1982
)
0.26
" However, there remains concern regarding low bioavailability and wide inter-individual differences in absorption and metabolism in humans, which suggests a great need to develop novel methods for resveratrol delivery."( Development of a lozenge for oral transmucosal delivery of trans-resveratrol in humans: proof of concept.
Blanchard, OL; Friesenhahn, G; Javors, MA; Smoliga, JM, 2014
)
0.4
" siRNA therapeutics are not optimal drug-like molecules due to poor bioavailability and immunogenic and off-target effects."( Therapeutic potential of chemically modified siRNA: Recent trends.
Mutisya, D; Prakash, S; Ranganna, K; Selvam, C; Thilagavathi, R, 2017
)
0.46
" Also, under a physiological cellular state, the bioavailability rate of D-ribose is much higher than that of glucose in diabetes, which makes this species much more active in protein glycation as compared with D-glucose."( Nonenzymatic glycosylation of isolated human immunoglobulin-G by D-ribose.
Ahmad, S; Al-Shaghdali, K; Alatar, AA; Faisal, M; Khan, MY; Khan, S; Rafi, Z; Rehman, S; Shahab, U; Tahir, IK, 2022
)
0.72
" Its anti-cancer and anti-inflammatory properties have been previously demonstrated, but its low bioavailability hampers its clinical use."( Quercetin-loaded solid lipid nanoparticles exhibit antitumor activity and suppress the proliferation of triple-negative MDA-MB 231 breast cancer cells: implications for invasive breast cancer treatment.
Hatami, M; Kheirollah, A; Khorsandi, L; Kouchak, M; Rashidi, M, 2023
)
0.91

Dosage Studied

Crosslinking with D-ribose is shown to affect cellular infiltration in a dose-response manner. When [14C]ribose was administered intraperitoneally to rats at a dosage of 300-750 mug (100-250 muCi)/10o g, approximately 1% of the radioactivity was recovered in the acid (5% CLCCCOOH)-INSOLUBLE MATERIAL OF THE LIVER NUCLEI 2 HR AFTER INJECTION. These results suggest a resveratrol-riboside matrix.

ExcerptRelevanceReference
" When [14C]ribose was administered intraperitoneally to rats at a dosage of 300-750 mug (100-250 muCi)/10o g, approximately 1% of the radioactivity was recovered in the acid (5% CLCCCOOH)-INSOLUBLE MATERIAL OF THE LIVER NUCLEI 2 HR AFTER INJECTION."( Natural occurrence of poly(ADP-ribosyl) histones in rat liver.
Hayaishi, O; Kawaichi, M; Omachi, A; Ueda, K, 1975
)
0.25
"Sixty-one patients with advanced disseminated cancer were given progressively increasing doses of pyrazofurin to evaluate toxicity patterns and to establish the dosage that produces maximum therapeutic effect with clinically tolerable toxicity."( A phase I study of pyrazofurin.
Bodey, GP; Burgess, MA; Freireich, EJ; Murphy, WK; Salem, PA, 1977
)
0.26
" These results may be accounted for by the low dosage used."( Sensitivity of central chemoreceptors controlling blood glucose and body temperature during glucose deprivation.
Fiorentini, A; Müller, EE, 1975
)
0.25
"Irreversible inactivation of striatal D2 dopamine (DA) autoreceptors with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) or inactivation of striatal guanine nucleotide binding proteins (G proteins) with pertussis toxin (PT) shifted the dose-response curve for N-n-propylnorapomorphine (NPA)-mediated inhibition of gamma-butyrolactone (GBL)-induced elevation of L-3,4-dihydroxyphenylalanine (L-DOPA) to the right, with a decrease in the maximum response."( The effects of pertussis toxin on dopamine D2 and serotonin 5-HT1A autoreceptor-mediated inhibition of neurotransmitter synthesis: relationship to receptor reserve.
Bohmaker, K; Bordi, F; Meller, E, 1992
)
0.28
"Multiple effects of pertussis toxin (PT) on Jurkat T-cells can be distinguished on the basis of their dose-response and their kinetics."( Pertussis toxin-sensitive G-proteins are not involved in activation of T-lymphocytes.
Breittmayer, JP; Cousin, JL; Fehlmann, M; Grenier-Brossette, N; Modesto, J, 1991
)
0.28
" These studies suggest the possibility of an extracellular mechanism of action of amiprilose hydrochloride and delineate acceptable dosage ranges for the potential drug."( Effects of amiprilose hydrochloride on the components of human skin equivalents.
Dimitrijevich, SD; Gracy, RW; Hevelone, JC, 1991
)
0.28
" We determined the adenine nucleotide de novo synthesis in the dog by infusion of [14C]glycine and the acceleration of adenine nucleotide built up by intracoronary infusion of ribose together with [14C]glycine or radiolabeled 5-amino-4-imidazolcarboxamide riboside or adenosine in the same animal model and with the same dosage of substrates (9 mmol) in postischemic and nonischemic myocardial tissue."( Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog.
Hoffmeister, HM; Mauser, M; Nienaber, C; Schaper, W, 1985
)
0.27
"09 microgram/day for six weeks) produced a more pronounced effect on the variables studied than did the moderate dosage (0."( Effect of 1 alpha-hydroxycholecalciferol on bone mass and composition of cortical bone in adult male rats.
Eriksson, S; Lindholm, TS; Nilsson, OS, 1981
)
0.26
" This technique has been used to generate dose-response curves describing the effects of mycophenolic acid and pyrazofurin on individual colonies of Chinese hamster ovary cells."( Ultrasensitive assay for ribonucleoside triphosphates in 50-1000 cells. Application to studies with pyrazofurin and mycophenolic acid.
Henderson, JF; Moyer, JD, 1983
)
0.27
" Treatment of cultures in each phase for 1 or 2 hrs resulted in threshold exponential type dose-response curves, yielding Do values of 3 and 1 microM, respectively."( Action of lycurim and pyrazofurin on hepatoma 3924A cells in culture.
Ban, J; Olah, E; Werber, G, 1982
)
0.26
" The T88A and T88S mutant receptor fully stimulated adenylyl cyclase, with the dose-response curves to CGS 21680 highly shifted to the right."( Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
Jacobson, KA; Jiang, Q; Kim, J; Van Rhee, AM; Wess, J; Yehle, S, 1996
)
0.29
" We developed a simple and reliable microassay based on N-ribohydrolase dosage using 4-nitrophenyl-beta-D-ribofuranoside (NPR) substrate for the quantification of Leishmania infantum."( Assessment of Leishmania promastigote growth in vitro by means of nucleoside hydrolase activity determination.
Derouin, F; Gangneux, JP; Garin, YJ; Meneceur, P; Pannier-Stockman, C; Sulahian, A, 2001
)
0.31
" Unfortunately, research subsequent to our study design has shown that D-ribose dosing higher than we used is needed to see a clinical effect and therefore no conclusions can be made from this study as to the efficacy of D-ribose."( Effects of oral administration of caffeine and D-ribose on mental fatigue.
Ataka, S; Kajimoto, O; Kajimoto, Y; Kuratsune, H; Mizuma, H; Mizuno, K; Nozaki, S; Shirai, T; Sugino, T; Tahara, T; Tanaka, M; Watanabe, Y, 2008
)
0.35
" Before dosing humans with [1'-(14)C]stavudine, a tissue distribution study was performed in Long-Evans rats."( Disposition of [1'-(14)C]stavudine after oral administration to humans.
Espina, RR; Iyer, RA; Kaul, S; Liu-Kreyche, P; Roongta, VA; Tran, SB; Warrack, BM; Zhou, L, 2010
)
0.36
" A dose-response dependence was observed in MTT assay."( Cell damage through pentose phosphate pathway in fetus fibroblast cells exposed to methyl mercury.
Amoli, JS; Barin, A; Ebrahimi-Rad, M; Sadighara, P, 2011
)
0.37
" After the presence of OS was established, treatment with PAR was started at the dosage of 300 mg of Potassium Bicarbonate and 150 mg of Ascorbic Acid in aqueous solution and changes occurring in OS biomarkers were followed dosing every three months."( Beckwith-Wiedemann syndrome: potassium ascorbate with ribose therapy in a syndrome with high neoplastic risk.
Anichini, C; Buonocore, G; di Bartolo, RM; Lo Rizzo, C; Longini, M; Paoli, G; Proietti, F, 2011
)
0.37
" Crosslinking with D-ribose is shown to affect cellular infiltration in a dose-response manner."( Nanophase bone substitute in vivo response to subcutaneous implantation.
Barbu, AM; Baskin, JZ; Eppell, SJ; McMasters, J; Soenjaya, Y; Vasanji, A, 2012
)
0.38
" To understand the in vivo relevance of this metabolic pathway, rats were dosed with PT and Rib-C2 was found in the urine."( Elucidation of the mechanism of ribose conjugation in a pyrazole-containing compound in rodent liver.
Fan, PW; Ford, KA; Khojasteh, SC; Le, H, 2013
)
0.39
" These results suggest a resveratrol-ribose matrix lozenge can achieve greater Cmax and enter the bloodstream faster than previously reported dosage forms for gastrointestinal absorption."( Development of a lozenge for oral transmucosal delivery of trans-resveratrol in humans: proof of concept.
Blanchard, OL; Friesenhahn, G; Javors, MA; Smoliga, JM, 2014
)
0.4
" The priority of the Cys reaction with different α-dicarbonyls and its dependence on the Cys dosage were investigated."( Formation Priority of Pyrazines and 2-Acetylthiazole Dependent on the Added Cysteine and Fragments of Deoxyosones during the Thermal Process of the Glycine-Ribose Amadori Compound.
Hayat, K; Ho, CT; Liu, M; Xu, H; Yu, J; Zhang, X; Zhou, T, 2022
)
0.72
" After evaluation of the tolerability and safety of the dosing regimens, a clinical recommended dose was determined for the dose-expansion part."( A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Li, H; Li, S; Ouyang, Q; Shao, B; Tong, Z; Wang, Y; Xu, G; Zhang, Q, 2022
)
0.72
" Olaparib and rucaparib are orally dosed twice a day, extensively metabolized by cytochrome P450 enzymes, and inhibitors of several enzymes and drug transporters with a high risk for drug-drug interactions."( Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology.
Beijnen, JH; Bruin, MAC; Huitema, ADR; Sonke, GS, 2022
)
0.72
" The current study detected the cardioprotective effect of olaparib at a dosage of 10 mg/kg/day."( Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice.
Abdo, VB; Ashour, RH; El Beltagy, HM; El Fatah, DSA; El-Karef, A; Elkatary, RG, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (14 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care5
Pet Supplies1
Active Lifestyle & Fitness4
Professional Supplements4

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Avalon Organics Wrinkle Therapy Cleansing Milk -- 8.5 fl ozAvalon OrganicsBeauty & Personal Carebenzyl alcohol, cetearyl alcohol, cetyl alcohol, citronellol, CoQ10, geraniol, glycerin, phenethyl alcohol, potassium hydroxide, ribose, sodium benzoate, sorbitol, stearic acid, ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Day Cream -- 1.75 ozAvalon OrganicsBeauty & Personal CareCetyl Alcohol, Citral, Citronellol, CoQ10, Geraniol, Glyceryl Stearate, Glycerin, Phenethyl Alcohol, Ribose, Sodium Benzoate, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Facial Serum -- 0.55 fl ozAvalon OrganicsBeauty & Personal Carecetyl alcohol, citral, citronellol, CoQ10, geraniol, glyceryl stearate, phenethyl alcohol, ribose, sodium benzoate, squalane, ubiquinone2024-11-29 10:47:42
Avalon Organics Wrinkle Therapy Firming Body Lotion with CoQ10 & Rosehip -- 8 fl ozAvalon OrganicsBeauty & Personal CareBenzyl Alcohol, Bisabolol, Cetyl Alcohol, Citral, Citronellol, CoQ10, Geraniol, Glycerin, Phenethyl Alcohol, Potassium Hydroxide, Ribose, Sodium Benzoate, Stearic Acid, Stearyl Alcohol, Ubiquinone2024-11-29 10:47:42
Bark & Whiskers Heart Health For Cats & Dogs -- 3.17 ozBark & WhiskersPet SuppliesTrimethylglycine, Trimethylglycine, Epigallocatechin Gallate, Glycine, L-Carnitine, Niacin, D-Ribose, Taurine2024-11-29 10:47:42
Cellev8 Focus and Memory - NSF Certified for Sport -- 4 Gummies Each / Pack of 20Cellev8Active Lifestyle & FitnessD-Ribose2024-11-29 10:47:42
Cellev8 Focus and Memory - NSF Certified for Sport -- 60 GummiesCellev8Active Lifestyle & FitnessD-Ribose2024-11-29 10:47:42
Cellev8 Inflammation and Recovery - NSF Certified for Sport -- 4 Gummies Each / Pack of 20Cellev8Active Lifestyle & FitnessD-Ribose2024-11-29 10:47:42
Cellev8 Inflammation and Recovery - NSF Certified for Sport -- 60 GummiesCellev8Active Lifestyle & FitnessD-Ribose2024-11-29 10:47:42
Designs for Sport Hydration Complex - NSF Certified for Sport Lemon-Orange -- 30 ServingsDesigns for SportProfessional SupplementsVitamin C, Calcium Ascorbate, Chloride, Potassium Bicarbonate, Quercetin, D-Ribose, Rutin, Taurine2024-11-29 10:47:42
Designs for Sport Mito NRG Complex - NSF Certified for Sport -- 120 Vegetarian CapsulesDesigns for SportProfessional SupplementsCoenzyme Q10, Creatine, L-Carnitine, Malic Acid, Manganese, Niacin, Pantethine, Vitamin B6, Trans-Resveratrol, Riboflavin, D-Ribose, Succinic Acid, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Douglas Laboratories Corvalen® Ribose Powder -- 9.9 ozDouglas LaboratoriesProfessional SupplementsD-Ribose2024-11-29 10:47:42
Klean Athlete Klean Endurance - NSF Certified for Sport Natural Orange Vanilla -- 90 Chewable TabletsKlean AthleteProfessional Supplementscitric acid, citric acid, microcrystalline cellulose, mannitol, D-Ribose, stearic acid, Xylitol2024-11-29 10:47:42
Sukin Purely Ageless Rejuvenating Day Cream -- 4.06 fl ozSukinBeauty & Personal Carebenzyl alcohol, cetyl alcohol, tocopherol, ethylhexylglycerin, tocopherol, vitamin e, glyceryl stearate, glycerin, lactic acid, phenoxyethanol, ribose, sodium benzoate, vanillin2024-11-29 10:47:42

Drug Classes (2)

ClassDescription
ribopyranoseThe pyranose form of ribose.
D-riboseA ribose in which the chiral carbon atom furthest away from the aldehyde group (C4') has the same configuration as in D-glyceraldehyde.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (3,702)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901857 (50.16)18.7374
1990's393 (10.62)18.2507
2000's601 (16.23)29.6817
2010's536 (14.48)24.3611
2020's315 (8.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials48 (1.25%)5.53%
Reviews160 (4.15%)6.00%
Case Studies25 (0.65%)4.05%
Observational0 (0.00%)0.25%
Other3,618 (93.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]